Atai life sciences announces results from the phase 1 iv-to-subcutaneous bridging study of pcn-101 (r-ketamine)

New york and berlin, aug. 08, 2023 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from perception neuroscience's phase 1 intravenous-to-subcutaneous bridging study of pcn-101 (r-ketamine).

ATAI Ratings Summary

ATAI Quant Ranking